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Extracorporeal membrane oxygenation (ECMO) has been used in more than 1,000 infants in 50 centers in
the United States. The extracorporeal circuit contains approximately 400 ml of blood, an amount exceeding the
blood volume of most full-term neonates. The effect of this additional blood volume on drug disposition is
unknown. In this study, we determined the pharmacokinetic parameters of gentamicin in 10 infants on ECMO.
Gentamicin concentrations were determined by a fluorescence polarization immunoassay. Pharmacokinetic
parameters were determined from these concentrations by using a two-compartment model. Our study
demonstrated a mean steady-state volume of distribution of 0.51 ± 0.11 liters/kg, a figure similar to that in
previous studies of full-term infants. The elimination half-life was found to be prolonged (mean, 573 ± 263
min). The creatinine level in the plasma of the infants was found to be a statistically significant predictor of
elimination half-life. Recommendations regarding initial dosing levels of gentamicin in infants on ECMO are
made.
Extracorporeal membrane oxygenation (ECMO) is a pro-
cess involving prolonged partial cardiopulmonary bypass
which is used to support life in infants dying of reversible
cardiopulmonary disease. The technique has been used in
more than 1,000 infants in 50 centers in the United States,
with approximately 80% surviving (2). During ECMO, blood
is drained from the right atrium, pumped through a silicon
membrane oxygenator, rewarmed, and then returned to the
aortic arch of the infant. The extracorporeal circuit contains
approximately 400 ml of blood, an amount exceeding the
blood volume of most full-term neonates (9). The effect of
this additional volume on drug disposition (distribution and
elimination) is not known. If drug disposition is substantially
altered in infants on ECMO, standard drug dosages and
dosing intervals may not be appropriate in these infants.
The purposes of this study were to determine the pharma-
cokinetics of gentamicin in infants on ECMO and to formu-
late an approach to gentamicin dosing regimens for this
group of babies.
MATERIALS AND METHODS
Infants were eligible for the study if they were started on
ECMO within the prior week at the Medical College of
Georgia and were receiving gentamicin. Ten infants were
prospectively included in the study. Two ECMO patients
were not included during the study period, owing to parental
refusal of consent in one case and nonavailability of the
investigators in another. The study was approved by the
Medical College of Georgia Human Assurance Committee,
and informed consent was obtained from a parent in each
case.
The extracorporeal circuit consisted of arterial and venous
cannulae (Argyle Chest Tubes; Sherwood Medical, St.
Louis, Mo.), extracorporeal tubing (Tygon Hancock Extra-
corporeal, Inc., King of Prussia, Pa.), a venous blood
reservoir (50-ml capacity; SciMed Life Systems, Minneapo-
lis, Minn.), a membrane lung (Kolobow, model 0800-2A;
* Corresponding author.
SciMed), and a heat exchanger (Omnitherm, model D-17-14;
SciMed), with a total blood volume of about 400 ml.
Gentamicin sulfate (10 mg/ml; Elkins-Sinn, Inc., Cherry
Hill, N.J.) was administered to all the infants soon after birth
in a dose of approximately 2.5 mg/kg based on birthweight.
Owing to weight increases seen in most of these infants after
birth, the actual weight-based doses studied ranged from
2.04 to 2.42 mg/kg. The doses of gentamicin were adminis-
tered over a 1-min infusion into the extracorporeal circuit via
a port distal to the venous-blood reservoir. The doses were
administered every 12 h in nine infants and every 18 h in one
infant.
Blood samples (2 ml each) were drawn from the extracor-
poreal circuit via a port proximal to the venous-blood
reservoir immediately before and 2, 15, 45, 120, 240, 480,
and 720 min after a dose of gentamicin was given. The
samples were collected during one dosing interval after the
third to ninth gentamicin doses. The samples were centri-
fuged, and the plasma was separated and frozen at -80°C
until analysis.
Gentamicin concentrations were determined by a fluores-
cence polarization immunoassay (TDX System; Abbott Lab-
oratories, Dallas, Tex.). The interday coefficient of variation
for this test over the range of values determined averaged
4.8%.
Creatinine levels in serum and blood urea nitrogen levels
were determined for each infant during the study period.
Urine output was estimated for each infant from diaper
weights.
Data analysis. For each individual, the gentamicin concen-
trations were fitted to a two-compartment model, assuming
elimination from the central compartment only, by using a
program for multiple-dose bolus injections (PCNONLIN;
Statistical Consultants, Inc., Lexington, Ky.). The pharma-
cokinetic parameters clearance (CL), volume of distribution
at steady state (Vs,), and terminal elimination half-life (tl,2,3)
were determined as follows: CL = dose/area under plasma
concentration-time curve (AUC), where AUC = A/a + B/I
and A, B, ot, and P are the intercepts and exponents
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TABLE 1. Patient characteristics
Birth wt Study wt Gestational Creatinine level BUNb Urine output
Infant Diagnosisa (kg) (kg) age (wk) in serum (mg/dl) (mg/dl) (ml/kg per h)
1 MAS 4.10 4.85 43 1.4 27 4.1
2 MAS/PFC 3.47 3.50 41 1.2 12 4.5
3 HMD 2.81 3.23 36 1.6 23 4.1
4 MAS 3.50 3.80 40 1.3 17 6.0
5 MAS/PFC 3.00 3.40 42 1.6 14 1.8
6 DH 2.69 2.69 38 1.1 11 4.2
7 MAS 4.30 4.27 41 0.8 17 2.8
8 MAS/PFC 3.20 3.87 40 2.5 23 1.9
9 PFC 3.19 3.58 Term 0.5 28 2.7
10 DH 2.54 2.94 40 1.3 13 1.5
a Abbreviations: MAS, meconium aspiration syndrome; PFC, persistent fetal circulation; HMD, hyaline membrane disease; DH, diaphragmatic hernia.
b BUN, Blood urea nitrogen.
determined from the model, and V,, = [(A/aX2 + B/p2) x
dose]/AUC2. Alpha and beta half-lives were determined
from the slopes of the initial and terminal portions of the
curve of the logarithm of the drug concentration versus time
by 4l/2a = 0.693/ao and t1/2, = 0.693/p, respectively.
From the calculated pharmacokinetic parameters, an op-
timal dosage was recalculated for each individual based on
the known Vss and P. The dosage was calculated to achieve
steady-state concentrations in plasma of 6 ,ug/ml 15 min after
intravenous injection (peak) and to achieve a trough of 1.5
,ug/ml immediately before the next dose. The dosage was
determined by a one-compartment open model to predict
steady-state dosage as follows:
Dose = [Cpeak x P x Vss x (1 - e- )]/e- (O.25)
where X = dosing interval, which is adjusted so that Ctrough
1.5 jig/ml.
In vitro studies. To determine whether the ECMO circuit
itself might sequester gentamicin, we injected a 3.0-mg dose
of gentamicin into an isolated circuit containing 370 ml of
blood. No decline in gentamicin levels was observed during
the 8-h sampling period.
Statistical analysis. Stepwise regression analysis of creati-
nine blood urea nitrogen levels in plasma, gestational age,
and urine output as possible predictors of the elimination
half-life was performed.
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FIG. 1. Gentamicin concentration versus time. Each point rep-
resents the mean concentration for 10 infants. The error bars
represent 1 standard deviation.
RESULTS
Nine of the ten infants studied survived. Selected charac-
teristics of the infants are presented in Table 1. Seven of the
infants had persistent fetal circulation and/or meconium
aspiration syndrome, two had a diaphragmatic hernia, and
one had hyaline membrane disease.
The estimated gestational age of the infants was between
36 and 43 weeks (as determined by the referring hospitals in
most cases), with infant no. 9 being characterized only as
"term." The creatinine levels in serum ranged from 0.5 to
2.4 mg/dl, the blood urea nitrogen levels in serum were
between 11 and 28 mg/dl, and the urine output ranged from
a low of 1.5 ml/kg per h to a high of 6.0 ml/kg per h.
Pharmacokinetics. The mean drug concentration versus
time curve for the 10 infants is illustrated in Fig. 1. The mean
concentrations of gentamicin in serum 45 min and 12 h after
infusion were 6.7 ± 1.25 and 2.60 ± 1.26 ,ug/ml, respectively.
The gentamicin pharmacokinetic parameters for each in-
fant are provided in Table 2. The mean parameters were as
follows: AUC, 3,300 ± 1,095 ug - min/ml (range, 1,554 to
4,790 .g. min/ml); Vs,, 0.51 ± 0.11 liters/kg (range, 0.36 to
0.71 liters/kg); CL, 2.78 ± 1.55 ml/min (range, 1.46 to 6.08
ml/min); and 4/2,1, 573 ± 263 min (range, 191 to 950 min). The
tl/2. ranged from 0.41 to 4.0 min (mean, 12.6 ± 13.0 min).
Linear regression analysis revealed the creatinine level in
serum to be a strong predictor of the gentamicin elimination
half-life (r2 = 0.668, P < 0.01). No influence of blood urea
nitrogen levels in serum, urine output, or gestational age on
half-life was found. Patient no. 9 was not included in these
analyses owing to the absence of a numerical gestational age
in the record.
TABLE 2. Pharmacokinetic parameters for gentamicin in
patients on ECMO
Optimal dose
Infant AUC t12P CL(p.g. min/ml) (min) (mUmin) (liters/kg) Dose r
(mg/kg) (h)
1 3,759 479 2.66 0.36 1.7 16
2 3,434 729 2.47 0.71 3.3 24
3 4,790 910 1.46 0.57 2.7 30
4 3,562 454 2.53 0.43 2.1 16
5 4,172 788 1.80 0.60 2.6 24
6 2,817 494 1.95 0.50 2.3 16
7 1,645 191 6.08 0.37 2.0 8
8 4,502 950 1.78 0.62 2.8 30
9 1,554 234 5.15 0.47 2.3 8
10 3,066 498 1.96 0.47 2.2 16
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DISCUSSION
Previous studies of full-term infants have demonstrated a
volume of distribution for gentamicin ranging from 0.5 to 0.6
liters/kg (3, 7, 10, 11). The values were similar in the infants
in our study, despite the additional approximately 400 ml of
circulating blood volume. The distribution of gentamicin
beyond the vascular space has apparently minimized the
effect of the additional blood volume.
The elimination half-life of gentamicin in newborns has a
wide range of reported values, with several studies demon-
strating an inverse relationship between gestational age and
half-life (1, 4). This relationship is usually explained as an
effect of the decreased glomerular filtration rate in infants of
less than 34 weeks postconceptive age (6). All of the infants
in our study had a gestational age of 35 weeks or more. A
relatively narrow range for gentamicin half-life (4.5 to 6.0 h)
is seen in the full-term neonate (4, 8, 11). The mean half-life
seen in our study (573 min) is unusually long. Since genta-
micin is cleared almost entirely by the kidneys (5), the
prolonged half-life may reflect renal injury with a reduced
glomerular filtration rate in this group of extremely ill
infants. We found creatinine concentrations in plasma to be
strongly correlated with the elimination half-life. Thomson et
al. (10) likewise found creatinine levels in plasma to be a
significant determinant of gentamicin disposition. Another
factor which one might consider for our group of infants is
the response of the kidneys exposed to nonpulsatile blood
flow. Under experimental conditions, nonpulsatile perfusion
of the kidneys of dogs results in diminished urine production
and sodium excretion (5). Glomerular filtration rate, how-
ever, is unaffected.
On the basis of our results, we can make recommenda-
tions regarding gentamicin dosing in infants on ECMO. By
using the methods described above, we determined the
retrospective ideal dosing regimens for each of our 10
patients (Table 2). For the group, the mean ideal dose was
2.4 + 0.5 mg/kg (range, 1.7 to 2.8 mg/kg) and the mean ideal
dosing interval was 18.8 + 8 h (range, 8 to 30 h). When
prescribing gentamicin for an infant on ECMO, therefore, a
dose of 2.5 mg/kg would be a reasonable starting point. The
appropriate dosing interval is more variable and will have to
be determined individually by monitoring concentrations in
serum over time. Finally, further dosage adjustments may be
necessary when ECMO is completed if gentamicin adminis-
tration is continued. The extent of these adjustments cannot
be predicted by the present study.
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